These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 21710166

  • 1. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey.
    Brah S, Chiche L, Fanciullino R, Bornet C, Mancini J, Schleinitz N, Jean R, Kaplanski G, Harlé JR, Durand JM.
    Ann Hematol; 2012 Feb; 91(2):279-85. PubMed ID: 21710166
    [Abstract] [Full Text] [Related]

  • 2. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, Kentos A, Pierre P, Boulet D, Bries G, Lê PQ, Janssens A, Delannoy A.
    J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
    [Abstract] [Full Text] [Related]

  • 3. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
    Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S, Fanin R.
    Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
    [Abstract] [Full Text] [Related]

  • 4. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
    Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M, Patriarca F, Soldano F, Isola M, De Luca S, Fanin R.
    Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
    [Abstract] [Full Text] [Related]

  • 5. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [Abstract] [Full Text] [Related]

  • 6. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C, Reu FJ, Ho AD, Hensel M.
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [Abstract] [Full Text] [Related]

  • 7. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
    Tran H, Brighton T, Grigg A, McRae S, Dixon J, Thurley D, Gandhi MK, Truman M, Marlton P, Catalano J.
    Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
    [Abstract] [Full Text] [Related]

  • 8. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
    Zhu YC, Wang W, Zhou YH, Wang XM, Wang X, Wang YL, Sun GZ, Hou M.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):163-7. PubMed ID: 21535953
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy and safety of two different low-dose rituximab regimens for Chinese adult patients with immune thrombocytopenia].
    Sui T, Zhang L, Zhou ZP, Xue F, Ge J, Yang RC.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Sep; 32(9):583-6. PubMed ID: 22338149
    [Abstract] [Full Text] [Related]

  • 10. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L, Alexandrescu D, Dutcher JP, O'Boyle KP, Eapen S, Wiernik PH.
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [Abstract] [Full Text] [Related]

  • 11. Long-term response to rituximab in patients with relapsing thrombotic thrombocytopenic purpura.
    Stein GY, Blickstein D, Orlin J, Sarig G, Inbal A.
    Isr Med Assoc J; 2011 Jul; 13(7):398-401. PubMed ID: 21838180
    [Abstract] [Full Text] [Related]

  • 12. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
    Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR, Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP.
    Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
    [Abstract] [Full Text] [Related]

  • 13. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
    Li Y, Wang XM, Mao M, Zhang XY, Fu L, Ai HM, Zhang LX.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608
    [Abstract] [Full Text] [Related]

  • 14. [Clinical therapeutic efficacy of rituximab for relapsed and refractory idiopathic thrombocytopenic purpura].
    Zhou LY, Zhang Z, Song LX, Gzhang X, Su JY, Li X, Chang CK.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):941-4. PubMed ID: 22931660
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center.
    Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, Schwarzinger M, Galicier L, Vanhille P, Vernant JP, Bordessoule D, Guidet B, Azoulay E, Mariotte E, Rondeau E, Mira JP, Wynckel A, Clabault K, Choukroun G, Presne C, Pourrat J, Hamidou M, Coppo P, French Thrombotic Microangiopathies Reference Center.
    Crit Care Med; 2012 Jan; 40(1):104-11. PubMed ID: 21926591
    [Abstract] [Full Text] [Related]

  • 16. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
    Zaja F, Marin L, Chiozzotto M, Puglisi S, Volpetti S, Fanin R.
    Am J Hematol; 2012 Mar; 87(3):321-3. PubMed ID: 22190262
    [Abstract] [Full Text] [Related]

  • 17. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP).
    Alasfoor K, Alrasheed M, Alsayegh F, Mousa SA.
    Ann Hematol; 2009 Mar; 88(3):239-43. PubMed ID: 18704420
    [Abstract] [Full Text] [Related]

  • 18. Low-dose rituximab in adult patients with primary immune thrombocytopenia.
    Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, Bocchia M, Medeot M, De Luca S, Ferrara F, Isola M, Baccarani M, Fanin R.
    Eur J Haematol; 2010 Oct; 85(4):329-34. PubMed ID: 20546023
    [Abstract] [Full Text] [Related]

  • 19. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
    Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, Marin L, Cavallin M, Bocchia M, Defina M, Ippoliti M, Ferrara F, Patriarca F, Avanzini MA, Regazzi M, Baccarani M, Isola M, Soldano F, Fanin R.
    Haematologica; 2008 Jun; 93(6):930-3. PubMed ID: 18403395
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
    Terrier B, Launay D, Kaplanski G, Hot A, Larroche C, Cathébras P, Combe B, de Jaureguiberry JP, Meyer O, Schaeverbeke T, Somogyi A, Tricot L, Zénone T, Ravaud P, Gottenberg JE, Mariette X, Cacoub P.
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.